Moreover, subsequent extensive cohorts and clinical trials could analyze the possibility of combining Phascolarctobacterium and/or Dialister with other validated biomarkers, such as PD-L1 expression or tumor mutational burden, in order to provide powerful predictive/prognostic signatures for immunotherapy in NSCLC. The gene discussed is CD274; the disease is neoplasm.